Author: Ravi Shankar

BEIJING, Nov. 13, 2026 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that it will report its unaudited consolidated results for the third quarter ended September 30, 2026, before the U.S. market opens on Wednesday, November 25, 2026.

The Company will host a conference call on Wednesday, November 25, 2026 at 8:00PM Beijing Time (7:00AM U.S. Eastern Time) to discuss the results.

Participants are required to pre-register for the conference call at:
https://register-conf.media-server.com/register/BIf96c3b4777a9434ba91b0e11741dc9da

Upon registration, participants will receive an email containing participant dial-in numbers and unique personal PIN. This information will allow you to gain immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

A live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.zhipin.com.

About KANZHUN LIMITED

KANZHUN LIMITED operates the leading online recruitment platform BOSS Zhipin in China. The Company connects job seekers and enterprise users in an efficient and seamless manner through its highly interactive mobile app, a transformative product that promotes two-way communication, focuses on intelligent recommendations, and creates new scenarios in the online recruiting process. Benefiting from its large and diverse user base, BOSS Zhipin has developed powerful network effects to deliver higher recruitment efficiency and drive rapid expansion.

For more information, please visit https://ir.zhipin.com.

For investor and media inquiries, please contact: 

KANZHUN LIMITED
Investor Relations
Email: ir@kanzhun.com

PIACENTE FINANCIAL COMMUNICATIONS
Email: kanzhun@tpg-ir.com

BEIJING, Nov. 13, 2026 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that it will report its unaudited consolidated results for the third quarter ended September 30, 2026, before the U.S. market opens on Wednesday, November 25, 2026.

The Company will host a conference call on Wednesday, November 25, 2026 at 8:00PM Beijing Time (7:00AM U.S. Eastern Time) to discuss the results.

Participants are required to pre-register for the conference call at:
https://register-conf.media-server.com/register/BIf96c3b4777a9434ba91b0e11741dc9da

Upon registration, participants will receive an email containing participant dial-in numbers and unique personal PIN. This information will allow you to gain immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

A live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.zhipin.com.

About KANZHUN LIMITED

KANZHUN LIMITED operates the leading online recruitment platform BOSS Zhipin in China. The Company connects job seekers and enterprise users in an efficient and seamless manner through its highly interactive mobile app, a transformative product that promotes two-way communication, focuses on intelligent recommendations, and creates new scenarios in the online recruiting process. Benefiting from its large and diverse user base, BOSS Zhipin has developed powerful network effects to deliver higher recruitment efficiency and drive rapid expansion.

For more information, please visit https://ir.zhipin.com.

For investor and media inquiries, please contact: 

KANZHUN LIMITED
Investor Relations
Email: ir@kanzhun.com

PIACENTE FINANCIAL COMMUNICATIONS
Email: kanzhun@tpg-ir.com

—Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO^® from another prophylactic therapy—

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of once-daily ORLADEYO^® (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older, showing reductions in hospitalizations and emergency department visits following ORLADEYO initiation in patients new to long-term prophylactic therapy (LTP) and in patients switching to ORLADEYO from another LTP.

This practice-informing research will be featured across two poster presentations during the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16. 

“These real-world studies add to our understanding of healthcare resource utilization among patients with HAE who either initiate ORLADEYO or switch from another long-term prophylactic therapy,” said Sandra Christiansen, MD, professor of medicine and director of translational research at the US HAEA Angioedema Center at the University of California, San Diego. “Patients initiating long-term prophylaxis were found to have comparable reductions in hospitalizations and emergency department visits for ORLADEYO, lanadelumab and subcutaneous plasma-derived C1-inhibitor. Patients who switched to ORLADEYO from an alternative first-line long-term prophylactic therapy experienced a decrease in their angioedema-related medical visits. Taken together, these findings support ORLADEYO’s clinical and economic benefits as a long-term prophylactic therapy for HAE.”  

A poster titled Reductions in Healthcare Utilization Among Individuals with HAE Who Switched to Berotralstat from Another Prophylaxis (Poster #R096) details findings from a retrospective pre-post study that featured analysis of administrative claims data of patients with HAE in the United States linked with proprietary data from the ORLADEYO patient base through BioCryst’s sole source specialty pharmacy. The analysis focused on individuals aged ≥12 years with HAE who switched from another LTP to ORLADEYO who had a baseline of at least six months of continuous insurance plan eligibility prior to starting ORLADEYO (n=78).

Patients with HAE who switched from another LTP to ORLADEYO experienced significant reductions in angioedema-related healthcare resource utilization. All statistical tests were two-sided, with an alpha level of 0.05. Results with p<0.05 were considered statistically significant:

• Overall angioedema-related visits decreased significantly by 30% per-patient-year (PPY) (p=0.039, sig)
• Rates of angioedema-related outpatient/emergency department visits decreased significantly by 30% PPY (p=0.040, sig)
• Rates of angioedema-related hospitalizations decreased to 0.12 PPY post-index (rate ratio [95% CI]: 0.54 [0.21–1.39], non-significant)

This poster will be on display in the expo hall of the Phoenix Convention Center and will be presented on Saturday, November 14, 11:30-11:45 a.m. MT.

A second poster titled Hospitalization and Emergency Department Reductions After Initiating Berotralstat, Lanadelumab, or Subcutaneous Plasma-Derived C1-Inhibitor for Hereditary Angioedema (Poster #R077) reported findings from a retrospective observational pre-post cohort study of all-cause and angioedema-related hospitalization and emergency department visits. The assessment focused on LTP treatment naïve patients aged ≥12 years who initiated treatment with ORLADEYO (n=128), lanadelumab (n=236) or subcutaneous plasma-derived C1-inhibitor (SC-pdC1-INH) (n=95) between June 2017 and October 2024 with ≥6 months of continuous insurance enrollment and evidence of HAE prior to LTP treatment initiation.

All cohorts experienced statistically significant reductions in emergency department visits and reductions were also observed in hospitalizations:

• Reductions in all-cause hospitalization ranged from -26% (SC-pdC1-INH cohort) to -53% (ORLADEYO cohort)
• Reductions in all-cause emergency department visits ranged from -34% (SC-pdC1-INH cohort) to -48% (lanadelumab cohort)
• Reductions in angioedema-related hospitalization ranged from -46% (SC-pdC1-INH cohort) to -59% (lanadelumab cohort)
• Reductions in angioedema-related emergency department visits ranged from -43% (SC-pdC1-INH cohort) to -61% (ORLADEYO cohort)
• No statistically significant differences in magnitude of reductions were observed between ORLADEYO and lanadelumab or SC-pdC1-INH

This poster will be on display in the expo hall of the Phoenix Convention Center and will be presented on Friday, November 13, 4:20-4:35 p.m. MT.

In addition to these real-world studies, BioCryst will also present new clinical data from its HAE portfolio designed to support diverse patient needs and preferences at the ACAAI 2026 Annual Scientific Meeting, including:

• Growth-Related Berotralstat Dose Adjustment in Children with Hereditary Angioedema: 48-Week Dosing Experience from APeX-P; Poster #R097; Monitor 15; Saturday, November 14, 11:45 a.m.-12:00 p.m. MT 
• Long-Term Safety, Efficacy, and Quality of Life with Navenibart in Hereditary Angioedema: ALPHA-SOLAR Interim Results; Poster #R110; Monitor 13; Sunday, November 15, 12:00-12:15 p.m. MT 

Visit www.ORLADEYO.com for more information. 

About ORLADEYO^® (berotralstat)
ORLADEYO^® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. One dose of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

U.S. Indication and Important Safety Information

INDICATION
ORLADEYO^® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation.

IMPORTANT SAFETY INFORMATION
An increase in QTc interval was observed in adults at dosages higher than 150 mg once daily and was concentration dependent.

The most common adverse reactions (≥10%) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain and gastroesophageal reflux disease.

In adult and pediatric patients aged 12 years and older with moderate or severe hepatic impairment (Child-Pugh B or C), the recommended dosage of ORLADEYO capsules is 110 mg once daily with food. In pediatric patients aged 2 to <12 years with moderate or severe hepatic impairment (Child-Pugh B or C), avoid use of ORLADEYO.

Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use of P-gp inducers with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. Concomitant use of ORLADEYO with CYP2D6 or CYP3A4 substrates can increase exposure of the CYP2D6 or CYP3A4 substrates and may increase the risk of adverse reactions associated with the substrates. If ORLADEYO is concomitantly used with CYP2D6 or CYP3A4 substrates where minimal increases in the concentration of the substrates may lead to serious adverse reactions, closely monitor or modify the dosage of the CYP2D6 or CYP3A4 substrate.

The safety and effectiveness of ORLADEYO in pediatric patients <2 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About navenibart
Navenibart is an investigational YTE-modified monoclonal antibody inhibitor of plasma kallikrein, an established and safe mechanism, currently being evaluated in clinical trials for long-term prevention of HAE attacks with potential best-in-class dosing every 3 or 6 months. 

About BioCryst Pharmaceuticals 
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the clinical and economic benefits of ORLADEYO and the development, potential dosing profile, competitive positioning, and expectations for navenibart. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: risks related to the development and interpretation of real-world data; BioCryst’s ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst’s ability to successfully progress its development plans for navenibart; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; ongoing and future clinical development of product candidates, including navenibart, may take longer than expected and may not have positive results; BioCryst may not advance human clinical trials with product candidates, including navenibart, as expected; the FDA or other applicable regulatory agencies may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates, may ultimately determine that there are deficiencies in the development program or execution thereof, may require additional information or studies, may disagree with our safety and efficacy conclusions, or may impose certain restrictions, warnings, or other requirements; product candidates, if approved, may not achieve market acceptance; and BioCryst’s ability to successfully commercialize its products and product candidates. This list is not exclusive. To see a more comprehensive set of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s forward-looking statements.

Contact:

Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update.

Business and Clinical Program Updates:

TTI-109 – Ulcerative Colitis (UC)

• Advancing development plans for TTI-109 in UC. Building on positive Phase 1 healthy volunteer results reported in July and the subsequent selection of UC as its initial target indication, Tvardi is preparing to advance TTI-109 into clinical development in UC, subject to clearance of our Investigational New Drug (IND) application and additional funding.
  • The Phase 1 results confirmed the prodrug design, with TTI-109 delivering TTI-101-equivalent exposure with improved tolerability and, across the active dose range, demonstrated reductions in cellular and humoral immune populations known to correlate with UC disease severity, providing pharmacodynamic evidence of STAT3 target engagement.
• Published additional preclinical data supporting STAT3 inhibition in UC. New findings published in the International Journal of Molecular Sciences demonstrated that, in a preclinical model of chronic colitis, TTI-101 achieved colon tissue exposure approximately eightfold higher than in plasma, normalized disease-associated changes in colon gene expression, muted colitis-associated changes in the gut microbiome and prevented the formation of colon adenocarcinomas, a long-term consequence of chronic colitis.
  • The preclinical data highlights the potential of STAT3 inhibition to address immune dysregulation, inflammation and fibrosis that drive UC progression. These findings build on prior preclinical studies in which TTI-101 and TTI-109 significantly reduced disease activity across three acute colitis models representing distinct immune axes.

TTI-101 – Hepatocellular Carcinoma (HCC)

• Advancing Phase 1b/2 REVERT LIVER CANCER study toward topline readout in early first quarter of 2027. The ongoing REVERT LIVER CANCER study is evaluating TTI-101 as monotherapy and in combination with established therapies in patients with HCC. The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation.

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”

Key Upcoming Milestones

• 2027: Initiation of clinical trial of TTI-109 in UC, subject to IND clearance and additional funding
• Early first quarter of 2027: TTI-101 Phase 1b/2 HCC topline data

Third Quarter 2026 Financial Results

Research and development expenses for the three months ended September 30, 2026, were $4.5 million, compared to $3.6 million for the comparable period in 2025. The increase was primarily driven by higher clinical costs associated with TTI-101.

General and administrative expenses were $1.9 million for the three months ended September 30, 2026, compared to $2.3 million for the three months ended September 30, 2025. The decrease was primarily driven by lower professional fees.

Net loss for the three months ended September 30, 2026, was $6.1 million, compared to a net loss of $5.5 million for the three months ended September 30, 2025.

Basic and diluted net loss per share attributable to common stockholders for the three months ended September 30, 2026, were both $(0.48), compared to basic and diluted net loss per share of $(0.59) for the three months ended September 30, 2025.

Cash and cash equivalents as of September 30, 2026, were $22.3 million, compared to cash, cash equivalents and short-term investments of $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash and cash equivalents will be sufficient to fund operations, as currently planned, into the third quarter of 2027. Advancing TTI-109 into UC and additional indications remain subject to additional funding and IND clearance.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in ulcerative colitis pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Cautionary Statement Regarding Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi’s product candidates; its ongoing clinical trials and anticipated timing of reporting data from such trials; potential indications for its product candidates; its anticipated cash runway; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in UC on the timelines expected or at all; the ability to replicate results for preclinical studies and early clinical trials in later trials; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the significant net losses Tvardi has incurred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

For Tvardi:
Tvardi Investor Relations
ir@tvardi.com

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com

TVARDI THERAPEUTICS Consolidated Balance Sheets (Unaudited, amounts in thousands, except share and per share amounts)
		As of September 30,				As of December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	22,275			$	20,734
Short-term investments			—				10,077
Prepaid expenses and other current assets			855				727
Total current assets			23,130				31,538
Property and equipment, net			28				52
Intangible assets, net			275				322
Operating lease right-of-use assets			83				144
Other non-current assets			17				17
Total assets		$	23,533			$	32,073
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	2,076			$	3,219
Accrued expenses			5,885				7,707
Operating lease liabilities, current portion			116				116
Total current liabilities			8,077				11,042
Operating lease liabilities, net of current portion			—				85
Total liabilities			8,077				11,127
Stockholders’ Equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 13,345,956 shares and 9,381,344 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively			13				9
Additional paid-in capital			145,278				131,379
Accumulated other comprehensive income			—				8
Accumulated deficit			(129,835	)			(110,450	)
Total stockholders’ equity			15,456				20,946
Total liabilities and stockholders’ equity		$	23,533			$	32,073

TVARDI THERAPEUTICS Consolidated Statements of Operations (Unaudited, amounts in thousands, except share and per share amounts)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Operating expenses:
Research and development		$	4,474			$	3,603			$	13,387			$	12,520
General and administrative			1,854				2,335				6,621				6,641
Total operating expenses			6,328				5,938				20,008				19,161
Loss from operations			(6,328	)			(5,938	)			(20,008	)			(19,161	)
Interest income			204				411				623				1,063
Other income, net			—				—				—				7,159
Net loss		$	(6,124	)		$	(5,527	)		$	(19,385	)		$	(10,939	)
Net loss per share attributable to common stockholders:
Basic		$	(0.48	)		$	(0.59	)		$	(1.85	)		$	(1.62	)
Diluted		$	(0.48	)		$	(0.59	)		$	(1.85	)		$	(2.50	)
Weighted-average common shares outstanding:
Basic			12,653,836				9,377,079				10,484,162				6,757,955
Diluted			12,653,836				9,377,079				10,484,162				7,244,785
Comprehensive loss:
Net loss		$	(6,124	)		$	(5,527	)		$	(19,385	)		$	(10,939	)
Unrealized (loss) gain on short-term investments			—				20				(8	)			7
Comprehensive loss		$	(6,124	)		$	(5,507	)		$	(19,393	)		$	(10,932	)

Filing is the key regulatory step toward acquiring the remaining 75.1% of Ark Financial Services; AtlasClear already owns 24.9%

• Dawson James has filed its continuing membership application (CMA) with FINRA, the principal regulatory approval required to close the acquisition of the remaining 75.1% of Ark Financial Services
• AtlasClear acquired an initial 24.9% of Ark in October 2026; Dawson James is already clearing through AtlasClearing
• Dawson James reported 2025 revenue of $25.1 million and audited net income of approximately $2.4 million
• Remaining consideration is cash and common stock only — no warrants, preferred stock, convertibles, discounts or price resets

TAMPA, Fla., Nov. 13, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (ATCH) (“AtlasClear” or the “Company”) today announced that Dawson James Securities, Inc. (“Dawson James”), a full-service investment bank headquartered in Boca Raton, Florida, has filed a continuing membership application (“CMA”) with the Financial Industry Regulatory Authority (“FINRA”) under FINRA Rule 1017 in connection with AtlasClear’s pending acquisition of the remaining 75.1% of Ark Financial Services, Inc. (“Ark”), the parent company of Dawson James. The application was filed on November 12, 2026.

FINRA approval of the CMA is required before a change in ownership of a FINRA member firm of this size can be completed, and it is the principal regulatory condition to closing the transaction. AtlasClear acquired an initial 24.9% of Ark’s equity on October 15, 2026, concurrently with the signing of a definitive agreement for the full acquisition.

“Filing the continuing membership application moves this transaction from signing onto the regulatory path to closing,” said John Schaible, Executive Chairman of AtlasClear Holdings. “Dawson James is a profitable, growing investment bank whose revenue more than doubled in 2025, and bringing it fully onto our platform is central to the vertically integrated firm we set out to build. We look forward to working constructively with FINRA through its review.”

Craig Ridenhour, President of AtlasClear Holdings and Chairman of AtlasClearing, Inc., added, “Dawson James is already clearing through AtlasClearing, so our two businesses are working together today. Full ownership lets us participate across the entire life of a transaction, from the capital raise through execution, clearing and settlement, and gives our correspondent clients access to an active underwriter. That is a combination we believe few firms serving small- and micro-cap issuers and investors can offer.”

Robert D. Keyser, Jr., Chief Executive Officer of Ark Financial Services and Dawson James Securities, said, “Our team has already seen the benefits of clearing through AtlasClearing. Becoming a wholly owned part of AtlasClear gives Dawson James an integrated clearing and capital markets platform that broadens what we can offer our issuer and institutional clients, and we look forward to completing the process with FINRA.”

Transaction Summary

Under the definitive agreement announced on October 15, 2026:

• Initial 24.9% investment (completed): $2.5 million in cash and a $2.5 million promissory note, paid to Ark’s majority stockholder. No AtlasClear shares were issued.
• Remaining 75.1% at closing: $2.4375 million in cash and $13.8125 million in AtlasClear common stock, valued at the five-day volume-weighted average price ending on the closing date.
• Deferred consideration: Up to $3.25 million, payable 25% in cash and 75% in stock, only if Dawson James meets its revenue targets for 2026 and 2027.
• Total consideration: Up to $24.5 million, consisting of approximately $8.25 million in cash and approximately $16.25 million in stock.
• Shareholder protections: No warrants, preferred stock, convertible securities, discounts or price resets. Ark stockholders receiving AtlasClear shares are subject to a six-month lock-up.

In addition, as is customary in broker-dealer acquisitions, Dawson James’s net capital in excess of $1.0 million at closing will be paid to Ark’s stockholders in cash or, at the majority stockholder’s election, in AtlasClear stock at the closing price.

Completion of the acquisition remains subject to FINRA approval of the CMA, AtlasClear stockholder approval to the extent required by the NYSE American Company Guide, and other customary closing conditions. There can be no assurance as to whether or when FINRA approval will be obtained or the transaction will close.

About Dawson James Securities, Inc.

Dawson James Securities, Inc. is a full-service investment firm providing investment banking, capital markets, institutional sales and trading, research and wealth management services. Headquartered in Boca Raton, Florida, Dawson James is an active placement agent and underwriter for small-cap and micro-cap companies across sectors including biotechnology, digital assets, defense, industrials and digital media. Dawson James is a member of FINRA and SIPC. For more information, visit www.dawsonjames.com.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, its pending acquisition of Ark Financial Services, Inc., and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear Holdings seeks to deliver a vertically integrated suite of investment banking, brokerage, clearing, risk management, regulatory, and commercial banking solutions. The Company’s common stock remains listed on the NYSE American, where trading has been suspended pending the Company’s appeal of the Exchange’s delisting determination, and is currently quoted on the OTC market under the symbol “ATCH.” For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would,” and similar expressions.

These statements include, but are not limited to, expectations regarding the onboarding and conversion of newly signed correspondent broker-dealers, the timing and amount of potential revenue contributions, expansion of the Company’s clearing, stock locate, stock loan, securities lending and margin businesses, operating efficiencies, anticipated benefits of strategic initiatives and proposed acquisitions, including the pending acquisition of Ark Financial Services, Inc., the planned acquisition of Commercial Bancorp of Wyoming and the proposed acquisition of an institutional digital asset business, the Company’s appeal of the NYSE American’s determination to delist its common stock and its ability to restore trading on the NYSE American, a potential reverse stock split, the quotation of the common stock on the OTC market, and future financial performance.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from those anticipated due to factors including the outcome of the Company’s appeal of the NYSE American’s determination to delist its common stock, the risk that trading in the common stock does not resume on the NYSE American and that the common stock is delisted, the Company’s ability to effect a reverse stock split and to satisfy the NYSE American’s continued listing standards, the limited liquidity and potential volatility of the common stock while it is quoted on the OTC market, the effect of the trading suspension or any delisting on the market price of the common stock, the Company’s ability to raise capital, and its existing agreements and pending acquisitions, the risk that a definitive agreement for the proposed acquisition of an institutional digital asset business, which is the subject of a non-binding letter of intent (other than certain customary provisions), is not executed, the risk that proposed acquisitions are not completed on the anticipated terms or at all, including the risk that the Ark Financial Services transaction does not receive FINRA approval or stockholder approval or satisfy other closing conditions, the failure to obtain required regulatory approvals, including for the acquisition of Commercial Bancorp of Wyoming, difficulties integrating acquired businesses or realizing their anticipated benefits, dilution from the issuance of AtlasClear common stock, delays in onboarding correspondent broker-dealers, failure of correspondent relationships to generate anticipated revenue, termination of clearing agreements, changes in economic or political conditions or applicable laws, changes in trading activity and market conditions, regulatory developments, challenges in executing the Company’s business strategy, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026.

AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact

AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact

Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) — (TSXV: NXLV) – NexLiving Communities Inc. (“NexLiving” or the “Company”) announced operating and financial results for the three and nine months ended September 30, 2026.

Stavro Stathonikos, President & CEO commented: “Our portfolio continues to demonstrate resiliency and growth, with same-property NOI increasing 4.6% and NOI margins improving 90 basis points in the third quarter. These results reflect strong execution by our team, continued investment in technology and cost discipline across the portfolio. This focus on operating efficiency translated into fully diluted FFO per share growth of 4.7% for the quarter and 9.4% for the first nine months of the year. With $13.2 million of cash on the balance sheet, we are well positioned to pursue accretive acquisitions and accelerate per-share growth.”

Summary of Results:

• Net operating income (“NOI”) increased by +3.6% to $5.5 million for the three months ended September 30, 2026.
• Same property NOI increased +4.6%, driven by a +3.0% increase in revenue, partially offset by a +0.6% rise in expenses for the three months ended September 30, 2026.
• Funds from operations (“FFO”) increased +4.5% to $2.3 million and fully diluted FFO per share increased +4.7% to $0.07 for the three months ended September 30, 2026.

Q3 2026 Operating and Financial Highlights:

As at	30-Sep-26			31-Dec-25			Change
Number of suites		2,050			2,073		(23	)
Average Occupancy		96.4	%		97.3	%	(90) bps
Net Debt to GBV*		67.1	%		68.7	%	(160) bps
Weighted average term to debt maturity (years)		3.4			3.5		(0.1) yrs
Weighted average contractual interest rate		3.37	%		3.11	%	26 bps
Net asset value		151,070,304			139,136,844		8.6	%
Net asset value per share	$	4.62		$	4.23		9.2	%

For the three months ended September 30,	2026		2025		Change
NOI	5,514,577		5,324,320		3.6	%
NOI margin	62.6	%	61.7	%	90 bps
FFO*	2,320,247		2,219,700		4.5	%
FFO per share – diluted*	0.07		0.07		4.7	%
FFO payout ratio*	14.3	%	15.0	%	(70) bps
Same property revenue*	8,751,383		8,492,874		3.0	%
Same property operating expenses*	(3,270,738	)	(3,252,836	)	0.6	%
Same property NOI*	5,480,645		5,240,038		4.6	%
Same property NOI margin*	62.6	%	61.7	%	90 bps

For the nine months ended September 30,	2026		2025		Change
NOI	16,061,369		15,412,249		4.2	%
NOI margin	60.8	%	59.7	%	110 bps
FFO*	6,017,373		5,518,682		9.0	%
FFO per share – diluted*	0.18		0.17		9.4	%
FFO payout ratio*	16.5	%	18.1	%	(160) bps
Same property revenue*	26,224,838		25,415,046		3.2	%
Same property operating expenses*	(10,290,064	)	(10,208,351	)	0.8	%
Same property NOI*	15,934,774		15,206,696		4.8	%
Same property NOI margin*	60.8	%	59.8	%	100 bps

*Refer to section “Non-IFRS Financial Measures”

Occupancy:

For the three months ended September 30, 2026, the Company’s wholly owned portfolio had an average occupancy rate of 96.4%, representing a decrease of 110 basis points from June 30, 2026. The decrease reflects normal course tenant turnover during the summer leasing period and was most pronounced in Quebec, where a large proportion of residential leases turn over on July 1.

Subsequent to quarter end, occupancy increased to 97.6% as at November 12, 2026, reflecting the re-leasing of vacant units subsequent to quarter end.

Fair Value of Investment Properties:

The Company’s overall weighted average capitalization rate at quarter end was 5.09%, compared to 5.04% at December 31, 2025. The Company recorded fair value gains on investment properties of $0.5 million for the three month period and $11.5 million for the nine month period, reflecting an upward revision to forecasted NOI, partly offset by higher capitalization rates.

Property Sale:

During September 2026, the Company completed the sale of four of the eight duplexes comprising its Rue du Progrès property in Gatineau, Quebec for gross proceeds of approximately $2.1 million. The Company used the proceeds to repay the $2.0 million mortgage that covered all eight duplexes and intends to dispose of the remaining four duplexes over the next 12 months.

As part of its ongoing portfolio optimization strategy, the Company continues to evaluate additional non-core assets for potential disposition.

NCIB Activity:

For the period July 1 to September 30, 2026, the Company purchased and cancelled a total of 170,400 shares pursuant to its NCIB for a total cost of $392,347, representing an average share price of $2.30.

Subsequent to September 30, 2026, the Company purchased and cancelled 83,300 shares for a total cost of $194,575 at an average of $2.34 per share. This brings NCIB activity for the year to 473,800 shares for a total cost of $1,050,453, representing an average share price of $2.22.

Dividend:

The Company’s Board of Directors has approved and declared a dividend of $0.01 per common share for the quarter ending December 31, 2026, representing $0.04 per share on an annualized basis. The dividend is payable on December 24, 2026, to shareholders of record at the close of business on December 4, 2026.

About the Company

NexLiving Communities Inc. (TSXV: NXLV) is a Canadian multi-family real estate company focused on acquiring, operating, and growing a portfolio of recently built and refurbished, highly leased residential properties in secondary markets across Canada.

NexLiving is developing a new standard in Canadian multi-family real estate, with a focus on long-term tenants who value proximity to healthcare, nature trails, parks, public transportation, and convenient services, and who hold modern, condo-style expectations of their homes and communities. The Company’s portfolio consists of Class A, low- and mid-rise buildings featuring modern and high-end finishes, elevators, heated underground parking, and a range of amenities designed to support a hassle-free, maintenance-free lifestyle. NexLiving aims to deliver exceptional living experiences to our residents and provide comfortable, affordable housing solutions that cater to a wide range of demographics. The Company currently owns 2,050 units in New Brunswick, Quebec, Ontario and Manitoba and has 108 townhomes under construction in the Barrhaven suburb of Ottawa, with construction expected to be completed in early 2027.

NexLiving is executing a disciplined and accretive growth strategy acquiring high-quality assets with strong day-one cash flow, optimizing operations, and recycling capital into higher-yielding opportunities. The Company continues to evaluate both acquisition targets and non-core asset dispositions as part of its ongoing portfolio optimization strategy, with a scalable growth pipeline extending well beyond 2026.

For more information about NexLiving, please refer to our website at www.nexliving.ca and our public disclosure at www.sedarplus.ca.

Forward-Looking Statements

This news release contains forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “projects”, “estimates”, “forecasts”, “intends”, “continues”, “anticipates”, or “does not anticipate” or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements contained in this news release include, but are not limited to, the payment of the declared dividend, the Company’s intention to dispose of the remaining duplexes at its Rue du Progrès property, and the expected completion of construction of the Barrhaven townhomes. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. These forward-looking statements reflect the current expectations of the Company’s management regarding future events and operating performance, but involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual events could differ materially from those projected herein and depend on a number of factors. These risks and uncertainties are more fully described in regulatory filings, which can be obtained on SEDAR+ at www.sedarplus.ca, under NexLiving’s profile, as well as under Risks and Uncertainties section of the MD&A released on November 12, 2026. Although forward-looking statements contained in this news release are based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release. Except as required by applicable securities laws, the Company does not undertake, and specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

Non-IFRS Financial Measures

The Company prepares and releases unaudited consolidated interim financial statements and audited consolidated annual financial statements prepared in accordance with IFRS. In this and other earnings releases, as a complement to results provided in accordance with IFRS, NexLiving discloses financial measures not recognized under IFRS which do not have standard meanings prescribed by IFRS. These include FFO, FFO (cents per share) – diluted, FFO payout ratio, Net Debt to GBV and same-property metrics (collectively, the “Non-IFRS Measures”). These Non-IFRS Measures are further defined and discussed in the MD&A dated November 12, 2026, which should be read in conjunction with this news release. Since these measures are not recognized under IFRS, they may not be comparable to similar measures reported by other issuers. The Company presents the Non-IFRS measures because management believes these Non-IFRS measures are relevant measures of the ability of NexLiving to earn revenue and to evaluate its performance and cash flows. A reconciliation of these Non-IFRS measures is included in the MD&A dated November 12, 2026. The Non-IFRS measures should not be construed as alternatives to net income (loss) or cash flows from operating activities determined in accordance with IFRS as indicators of the Company’s performance.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information please contact:
Stavro Stathonikos
sstathonikos@nexliving.ca
647-847-2030

• JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026
• JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027
• JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027
• JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027
• Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update.

“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones,” said Tom Frohlich, Chief Executive Officer of Jade. “We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile. We also expect to advance JADE301 into the clinic this quarter, which, alongside JADE101 and JADE201, will give us three clinical-stage programs heading into 2027. With multiple clinical catalysts expected across our pipeline next year, we see significant opportunities to further demonstrate the differentiated profiles of our programs and ultimately deliver meaningful new therapies for patients with autoimmune disease.”

Pipeline and Corporate Updates

JADE101: anti-APRIL monoclonal antibody for IgA nephropathy (IgAN)

• Jade expects to initiate EVERGREEN, a Phase 3 registrational trial of JADE101 in IgAN, in the fourth quarter of 2026, reflecting the Company’s rapid execution as JADE101 advances into registrational development. A Trial-in-Progress poster describing EVERGREEN was presented at the American Society of Nephrology (ASN) Kidney Week 2026.
• Enrollment in the Phase 2 JUNIPER trial of JADE101 in IgAN is ongoing, with interim data expected in the second quarter of 2027. A Trial-in-Progress poster describing JUNIPER was presented at ASN Kidney Week 2026.

JADE201: anti-BAFF-R monoclonal antibody for autoimmune diseases

• The Phase 1 clinical trial evaluating JADE201 in participants with rheumatoid arthritis is ongoing, with interim biomarker-rich data expected in 2027 to inform indication prioritization.

JADE301: anti-IFN-β monoclonal antibody for dermatomyositis

• Jade presented preclinical data at the 2026 European Academy of Dermatology and Venereology (EADV) Congress supporting the potentially differentiated profile of JADE301 in dermatomyositis. Key results included:
  • JADE301 demonstrated selective, high-affinity binding to IFN-β and greater functional potency than a dazukibart comparator in disease-relevant human cells.
  • Following subcutaneous (SC) administration in non-human primates, JADE301 demonstrated an approximately 25-day half-life and was well tolerated at all dose levels evaluated, supporting the potential for infrequent SC dosing.
• Jade expects to initiate a Phase 1 trial of JADE301 in healthy volunteers in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.

Corporate

• Expanded Brad Dahms’ role and title to Chief Financial Officer and Chief Business Officer. Mr. Dahms will continue to oversee the Company’s finance and investor relations functions and will now also lead business development and corporate strategy as Jade advances its pipeline toward multiple clinical readouts in 2027.

Third Quarter 2026 Financial Results

• Cash Position: As of September 30, 2026, Jade had cash, cash equivalents, and investments of $475.7 million. Based on its current operating plans, Jade believes that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2028.
• Research and Development (R&D) expenses: R&D expenses were $30.8 million for the third quarter ended September 30, 2026, an increase of $8.8 million compared to the third quarter of 2025, and included $3.6 million in stock-based compensation expense. R&D expenses increased primarily due to increased costs around chemistry, manufacturing and controls, clinical activity, and personnel-related costs and related stock-based compensation expense.
• General and Administrative (G&A) expenses: G&A expenses were $8.8 million for the third quarter ended September 30, 2026, an increase of $3.4 million compared to the third quarter of 2025, and included $3.5 million in stock-based compensation expense. The increase in G&A expenses was primarily due to higher personnel-related costs and related stock-based compensation expense.
• Net loss: Net loss totaled $35.1 million for the third quarter ended September 30, 2026, compared to $25.2 million for the third quarter of 2025. Net loss increased primarily due to higher R&D and G&A expenses, as described above.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation: Jade’s ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and JADE301 and their best-in-class potential; Jade’s plans to conduct a Phase 3 clinical trial of JADE101, the design and timing thereof and Jade’s expectations that such trial will serve as a registrational study; the expected timelines for the initiation of the Phase 1 clinical trial of JADE301 and for the availability of interim data from the Phase 2 clinical trial of JADE101 and the Phase 1 clinical trials of JADE201 and JADE301; expectations regarding the type of data anticipated to be received from the Phase 1 clinical trial of JADE201; the potential therapeutic uses, efficacy, durability, safety profiles, and dosing of JADE101, JADE201 and JADE301; and the potential for Jade’s cash, cash equivalents and investments to provide runway into the fourth quarter of 2028. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: interim results of a clinical trial are not necessarily indicative of final results and one or more of the outcomes may materially change following more comprehensive reviews of the data, as follow-up on the outcome of any particular participant continues and as more participant or final data becomes available; predicted data for JADE101 may not be realized in actual clinical studies; the ongoing and planned clinical trials of JADE101, JADE201 and JADE301 and any other clinical trials may be delayed or may not demonstrate desirable efficacy or predicted performance; Jade’s planned JADE101 Phase 3 clinical trial may be delayed based on FDA feedback or requirements, as the FDA retains broad discretion to require additional clinical data for any product candidate prior to the conduct of a Phase 3 clinical trial or submission for regulatory approval; even if such Phase 3 trial is successful, it may not support regulatory approval; adverse events and safety signals may occur; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may be delayed to a point where they are not commercially viable; clinical trial start up, enrollment or regulatory challenges may occur; challenges associated with Jade’s dependence on third-party vendors for the development, manufacture and supply of its product candidates may occur; Jade may use its capital resources sooner than expected; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Zane Goodwin
IR@JadeBiosciences.com
Media@JadeBiosciences.com

	JADE BIOSCIENCES, INC.
	CONDENSED CONSOLIDATED BALANCE SHEETS
	(In thousands, except share amounts)
			September 30, 2026				December 31, 2025
	Cash, cash equivalents and investments		$	475,706			$	336,158
	Other assets			10,685				13,623
	Total assets		$	486,391			$	349,781
	Total liabilities		$	30,887			$	17,263
	Total stockholders’ equity			455,504				332,518
	Total liabilities and stockholders’ equity		$	486,391			$	349,781
	JADE BIOSCIENCES, INC.
	CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
	(In thousands, except share and per share amounts)
			Three Months Ended September 30, 2026				Three Months Ended September 30, 2025				Nine Months Ended September 30, 2026				Nine Months Ended September 30, 2025
	Operating expenses
	Research and development(1)		$	30,823			$	22,010			$	116,941			$	64,580
	General and administrative(2)			8,817				5,391				25,060				13,983
	Total operating expenses			39,640				27,401				142,001				78,563
	Loss from operations			(39,640	)			(27,401	)			(142,001	)			(78,563	)
	Other income (expense):
	Interest income			4,629				2,254				10,959				4,697
	Change in fair value of Convertible Notes payable(3)			—				—				—				(21,584	)
	Other expense			(34	)			(28	)			(105	)			(28	)
	Total other income (expense), net			4,595				2,226				10,854				(16,915	)
	Net loss before income tax expense			(35,045	)			(25,175	)			(131,147	)			(95,478	)
	Income tax expense			(10	)			—				(41	)			—
	Net loss			(35,055	)			(25,175	)			(131,188	)			(95,478	)
	Other comprehensive income (loss):
	Currency translation adjustment		$	13			$	18			$	(58	)		$	(6	)
	Unrealized gain (loss) on investments		$	(1,419	)		$	35			$	(2,137	)		$	35
	Comprehensive loss		$	(36,461	)		$	(25,122	)		$	(133,383	)		$	(95,449	)
	Net loss per share attributable to common stockholders, basic and diluted		$	(0.42	)		$	(0.48	)		$	(1.72	)		$	(3.08	)
	Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted		$	(415.39	)		$	(482.25	)		$	(1,721.52	)		$	(3,081.78	)
	Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted			71,763,164				39,584,489				63,581,599				23,816,586
	Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted			12,622				12,622				12,622				7,166
	(1) Includes related party amounts of $0.3 million and $17.6 million for the three and nine months ended September 30, 2026, respectively, and $5.8 million and $17.5 million for the three and nine months ended September 30, 2025, respectively.
	(2) Includes no related party amount for the three months ended September 30, 2026 and $0.2 million for the nine months ended September 30, 2026. Includes related party amounts of $0.2 million for each of the three and nine months ended September 30, 2025.
	(3) Includes $4.6 million for the nine months ended September 30, 2025.

Tel Aviv, Israel, Nov. 13, 2026 (GLOBE NEWSWIRE) — Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW), today announced that, as previously announced by its subsidiary, Fort Technology Inc. (Nasdaq: FRTT, TSXV: FORT) (“Fort”), Fort has entered into securities purchase agreements with two institutional investors (the “Investors”), pursuant to which Fort may issue and sell, from time to time, unsecured convertible promissory notes (the “Notes’) in an aggregate principal amount of up to $20,000,000, together with warrants to purchase Fort common shares, subject to the terms and conditions of the agreements.

Fort intends to use the net proceeds from the financing for general working capital and to support its operations, including, among other things, the activities of its majority-owned subsidiary Logia USA Inc. related to fuel integrity solutions for data centers and other mission-critical facilities.

The Notes, which are subject to a 10% original issue discount, will be issued in an initial tranche with an aggregate principal amount of $2,200,000 across both Investors, for aggregate gross proceeds of $1,980,000, followed by additional quarterly tranches, at Fort’s discretion, with aggregate principal amounts of up to $2,200,000 across both Investors  (with the final tranche having an aggregate principal amount of up to $2,400,000), subject to the terms of the agreements. The issuance of additional tranches is subject to satisfaction or waiver of the applicable closing conditions, and there can be no assurance that the full $20 million will be funded. The Notes bear interest at 8% per annum, mature 28 months after their respective issuance dates, and are convertible into common shares of Fort at the lower of a fixed price and 88% of the lowest daily VWAP during the 20 trading days preceding conversion, subject to a floor price. Concurrently with the issuance of each Note, the applicable Investor will receive warrants to purchase common shares of Fort, exercisable for five years. In addition, Fort has agreed to issue to the Investors, at the initial closing, common shares with an aggregate value of $1,000,000 as a commitment fee, with the number of shares determined based on the average daily VWAP during the three trading days immediately preceding the initial closing date.

The securities to be issued have not been registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Fort Technology

Fort is engaged in the retail sale of consumer products, primarily serving the pest control and remedial repair industries. Fort develops, markets and sells a range of products for both amateur and professional customers under its proprietary brands, including Roshield, Entopest, Rempro and BirdGo. Products are sold primarily through Amazon marketplaces in the United Kingdom and Europe as well as through other online sales channels. Fort currently serves customers throughout the United Kingdom and continental Europe and plans to expand its retail operations into the United States, subject to applicable regulatory approvals, including through the acquisition of Logia USA Inc., a company focused on selling advanced fuel integrity solutions for data centers and other mission-critical facilities in the United States.

About Nexera Technologies Ltd

Nexera Technologies Ltd operates, through its subsidiaries, in the fields of advanced technologies for the global homeland security, or HLS, sector and e-commerce. Its operations are conducted through three principal lines of business: KeepZone AI Inc., or KeepZone, a wholly-owned subsidiary dedicated to distributing and promoting AI-powered homeland security technologies, including 3D imaging and electromagnetic threat detection, perimeter intrusion detection, counter-unmanned aircraft systems, and multi-layered security solutions for critical infrastructure and global markets; Fort Products Limited, a legacy consumer products operation focused on pest control and remedial products, which was sold to Fort Technology Inc., or Fort Technology, in July 2025 in exchange for a controlling equity interest, with the Company having since reduced its stake in Fort while retaining control and strategic involvement in related e-commerce activities; and its ongoing legacy e-commerce activities, consisting of data-driven online retail operations (primarily on the Amazon Marketplace) conducted through the Company’s other wholly-owned subsidiaries, including Smart Repair Pro and Top Rank Ltd.

For more information on Nexera Technologies, visit: https://nexera-tech.io/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate,” or other comparable terms. For example, the Company is using forward-looking statements when discussing the anticipated issuance of the Notes in an aggregate principal amount of up to $20 million, including the initial and any additional tranches, subject to the terms and the conditions of the securities purchase agreements; Fort’s intended use of the net proceeds for general working capital and to support its operations, including the activities of Logia USA Inc.; and the anticipated issuance of warrants and common shares as payment of commitment fees to the Investors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to adapt to significant future alterations in Amazon’s policies; the Company’s ability to sell its existing products and grow the Company’s brands and product offerings; the Company’s ability to meet its expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of conditions in Israel; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”), on April 1, 2026, and the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact

Michal Efraty
Adi and Michal PR-IR
Investor Relations, Israel
michal@efraty.com 

13 November 2026

LEI: 2138003QW2ZAYZODBU23

LSE Code: 3OIS

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY
(a public company incorporated with limited liability in Ireland)
WISDOMTREE WTI CRUDE OIL 3X DAILY SHORT SECURITIES
ISIN: XS2819844387

PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES
ADJOURNMENT OF MEETING OF THE ETP SECURITYHOLDERS

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser.

If you have sold or transferred all of your WisdomTree WTI Crude Oil 3x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee or stockbroker, banker or other agent through whom the sale or transfer was made, for onward transmission to the purchaser or transferee.

The Issuer wishes to announce that the Meeting of the holders of the Affected Securities scheduled for Friday 13 November 2026, at 11:00 a.m. (the “Original Meeting”) has been adjourned, in accordance with paragraph 20 of Schedule 7 of the Trust Deed, for lack of a quorum. The adjourned meeting will be reconvened on 11:00 a.m. on Monday 7 December 2026, being a date not more than 30 days after the Original Meeting, and will be held at the offices of Apex IFS Limited in 2nd Floor, Block 5, Irish Life Centre, Abbey Street Lower, Dublin 1, D01P767, Ireland (the “Adjourned Meeting”).

The Adjourned Meeting is being held to consider certain amendments to documentation, made under the powers set out in clause 2 of schedule 7 of the master trust deed of the Affected Securities, required to effect a reduction in the principal amount of the Affected Securities from USD0.14 to USD0.014. This follows the price of the Affected Securities falling below 500 per cent. of its current principal amount on 16 October 2026, and is designed to maintain the normal trading and operations of the Affected Securities. Full details of the Proposal and Extraordinary Resolution are set out in the notice dated 21 October 2026.

Under article 11.5 of the Issuer’s Articles of Association, no further notification is required for the Adjourned Meeting. Holders of the Affected Securities are therefore directed to the original notification, including the circular dated 21 October 2026, and also a revised form of proxy for the Adjourned Meeting, which are available on the website of the Issuer at https://www.wisdomtree.eu/en-gb/resource-library/prospectus-and-regulatory-reports#tab-2A942D42-5AA1-4008-9080-3C2DADB050A7.

Holders of the Affected Securities should note that a duly completed voting instructions already made in respect of the Original Meeting will NOT continue to be valid for the Adjourned Meeting. Holders of the Affected Securities should therefore not rely on any voting instructions already made in respect of the Original Meeting and should therefore make arrangements to vote again on the matters being considered, in order to participate in the Adjourned Meeting.

Holders of the Affected Securities are advised to check with any bank, securities broker or other intermediary through which they hold their Affected Securities when such intermediary would need to receive instructions from a holder of Affected Securities in order for such holder of Affected Securities to participate in the Adjourned Meeting by the deadlines specified in this circular. The deadlines set by any such intermediary and each ICSD for the submission instructions will be earlier than the relevant deadlines specified in the circular.

In relation to the delivery instructions or obtaining voting certificates or otherwise making arrangements for the giving of voting instructions, in each case through the ICSDs, holders of the Affected Securities should note the particular practice and policy of the relevant ICSDs, including any earlier deadlines set by such ICSD. The deadlines set by any intermediary or by the ICSDs will be earlier than the deadlines set out in the circular.

In accordance with normal practice, The Law Debenture Trust Corporation p.l.c., as trustee, expresses no opinion as to the merits of the Proposal, the terms of which were not negotiated by it. It has however authorised it to be stated that, on the basis of the information contained in the original circular and in this document (which it advises holders of Affected Securities to read carefully) it has no objection to the form in which the Proposal and Notice of Meeting are presented to holders of Affected Securities for their consideration.

Holders of the Affected Securities will be notified of the outcome of the Adjourned Meeting shortly thereafter.

13 November 2026

LEI: 2138003QW2ZAYZODBU23

LSE Code: 3OIS

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY
(a public company incorporated with limited liability in Ireland)
WISDOMTREE WTI CRUDE OIL 3X DAILY SHORT SECURITIES
ISIN: XS2819844387

PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES
ADJOURNMENT OF MEETING OF THE ETP SECURITYHOLDERS

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser.

If you have sold or transferred all of your WisdomTree WTI Crude Oil 3x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee or stockbroker, banker or other agent through whom the sale or transfer was made, for onward transmission to the purchaser or transferee.

The Issuer wishes to announce that the Meeting of the holders of the Affected Securities scheduled for Friday 13 November 2026, at 11:00 a.m. (the “Original Meeting”) has been adjourned, in accordance with paragraph 20 of Schedule 7 of the Trust Deed, for lack of a quorum. The adjourned meeting will be reconvened on 11:00 a.m. on Monday 7 December 2026, being a date not more than 30 days after the Original Meeting, and will be held at the offices of Apex IFS Limited in 2nd Floor, Block 5, Irish Life Centre, Abbey Street Lower, Dublin 1, D01P767, Ireland (the “Adjourned Meeting”).

The Adjourned Meeting is being held to consider certain amendments to documentation, made under the powers set out in clause 2 of schedule 7 of the master trust deed of the Affected Securities, required to effect a reduction in the principal amount of the Affected Securities from USD0.14 to USD0.014. This follows the price of the Affected Securities falling below 500 per cent. of its current principal amount on 16 October 2026, and is designed to maintain the normal trading and operations of the Affected Securities. Full details of the Proposal and Extraordinary Resolution are set out in the notice dated 21 October 2026.

Under article 11.5 of the Issuer’s Articles of Association, no further notification is required for the Adjourned Meeting. Holders of the Affected Securities are therefore directed to the original notification, including the circular dated 21 October 2026, and also a revised form of proxy for the Adjourned Meeting, which are available on the website of the Issuer at https://www.wisdomtree.eu/en-gb/resource-library/prospectus-and-regulatory-reports#tab-2A942D42-5AA1-4008-9080-3C2DADB050A7.

Holders of the Affected Securities should note that a duly completed voting instructions already made in respect of the Original Meeting will NOT continue to be valid for the Adjourned Meeting. Holders of the Affected Securities should therefore not rely on any voting instructions already made in respect of the Original Meeting and should therefore make arrangements to vote again on the matters being considered, in order to participate in the Adjourned Meeting.

Holders of the Affected Securities are advised to check with any bank, securities broker or other intermediary through which they hold their Affected Securities when such intermediary would need to receive instructions from a holder of Affected Securities in order for such holder of Affected Securities to participate in the Adjourned Meeting by the deadlines specified in this circular. The deadlines set by any such intermediary and each ICSD for the submission instructions will be earlier than the relevant deadlines specified in the circular.

In relation to the delivery instructions or obtaining voting certificates or otherwise making arrangements for the giving of voting instructions, in each case through the ICSDs, holders of the Affected Securities should note the particular practice and policy of the relevant ICSDs, including any earlier deadlines set by such ICSD. The deadlines set by any intermediary or by the ICSDs will be earlier than the deadlines set out in the circular.

In accordance with normal practice, The Law Debenture Trust Corporation p.l.c., as trustee, expresses no opinion as to the merits of the Proposal, the terms of which were not negotiated by it. It has however authorised it to be stated that, on the basis of the information contained in the original circular and in this document (which it advises holders of Affected Securities to read carefully) it has no objection to the form in which the Proposal and Notice of Meeting are presented to holders of Affected Securities for their consideration.

Holders of the Affected Securities will be notified of the outcome of the Adjourned Meeting shortly thereafter.